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OBJECTIVES: To compare 12-month adherence to liraglutide once daily (QD) or 
exenatide once weekly (QW) between commercially insured patients with type 2 
diabetes mellitus (T2DM) newly initiating liraglutide QD or exenatide QW in the 
U.S. METHODS: This retrospective cohort study used U.S. administrative claims 
data to study patients with T2DM initiating liraglutide QD or exenatide QW (initiated 
therapy= index therapy). Patients were included if they had T2DM, were glucagon-
like peptide-1 receptor agonist (GLP-1RA)–naïve, initiated liraglutide QD or exenatide 
QW from 2/1/2012–10/1/2012 (date of initiation= index), were aged ≥ 18y at index, 
and had continuous enrollment for 12 months before (baseline) to 12 months after 
index (follow-up). The study outcome was index GLP-1RA adherence (proportion 
of days covered [PDC] during follow-up, dichotomized at ≥ 80% versus < 80%, and 
at ≥ 90% versus < 90%). These PDC thresholds have been shown to be predictive of 
reduced hospitalization and mortality for patients with diabetes. Multivariable logis-
tic regressions compared adherence between the GLP-1RAs, adjusting for potential 
confounders. Sensitivity analyses were performed separating liraglutide QD by dose 
(1.2 mg/1.8 mg). RESULTS: Study sample included 10,829 liraglutide QD (4,945 1.2 
mg; 5,884 1.8 mg) patients and 3,173 exenatide QW patients. In each group, mean age 
was approximately 52 years and the proportion of females was 50% for exenatide 
QW and 54% for liraglutide QD. In multivariable-adjusted analyses, liraglutide QD 
patients had statistically significant lower odds of achieving a PDC≥ 80% (odds ratio 
[OR] treating exenatide QW as reference= 0.888, P= .007, 95% confidence interval 
[CI]= 0.816 to 0.968) and statistically significant lower odds of achieving a PDC≥ 90% 
(OR= 0.757, P< .001, 95% CI= 0.690 to 0.831) than exenatide QW patients. In sensitivity 
analyses, results when separating liraglutide QD by dose were directionally consist-
ent. CONCLUSIONS: Patients receiving exenatide QW had greater adjusted odds 
of clinically significant adherence thresholds compared with patients receiving 
liraglutide QD in this retrospective analysis.
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OBJECTIVES: To assess the barriers to treatment adherence on disease manage-
ment of acromegaly from the provider prospective METHODS: A web-based cross-
sectional survey was conducted from August –October, 2014. Healthcare providers 
who had experience in treating acromegaly patients were asked about barriers to 
treatment adherence and influence on the treatment algorithm based on their 
experiences and perspectives. RESULTS: A total of 23 providers (mean age: 56 
years, female: 48%) completed the survey, including physicians (52%), nurses or 
nurse practitioners (43%) and research coordinators (5%). Most worked at academic 
hospitals (78%). Their specialties included endocrinology & metabolism (70%), neu-
roendocrinology (22%) and neurosurgery (8%). Of the providers, 62% had more than 
10 years of experience (range: 5-40 years) treating acromegaly; 75% of them were 
concerned about the barriers to pharmacological treatment adherence. The great-
est concerns were side effects (100%), financial issues (89%), and the therapy being 
too complicated or inconvenient to patients (56%). Seventy percent (5 MDs and 
11 nurses) had encountered patients with symptoms that became worse toward 
the end of an injection cycle, 80% of physicians adjusted the treatment algorithm 
accordingly. Of 9 nurses who had experiences with somatostatin analog (SSA) 
injections, 67% of them raised concerns, of which the most common were side 
effects (e.g., pain, erythema, hematoma), and time loss due to injections. When 
considering the patient’s specific needs, all physicians and nurses with SSA injec-
tion experience (n= 21) would consider offering an oral therapy to patients if it had 
comparable efficacy and safety to the current long acting SSA treatments. The top 
three determinants to drive decisions in acromegaly maintenance therapy were 
clinical guidelines, lower out-of-pocket cost for the patient, and lower total medical 
costs. CONCLUSIONS: Study results indicated that treatment side effects, financial 
issues, and inconvenience were the leading barriers to treatment adherence from 
the healthcare provider perspective.
PDB69
valiDation of PrescriPtion meDication aDherence PreDiction tool 
(rxaPt) to PreDict non-aDherence among DiaBetes Patients enrolleD 
in meDicare
Mhatre SK1, Sansgiry S2, Serna O3, Sansgiry SS1
1University of Houston, Houston, TX, USA, 2VA Medical Center, Houston, TX, USA, 3Cigna 
HealthSpring, Houston, TX, USA
OBJECTIVES: Adherence to diabetes medications in the Medicare population is 
low, which can greatly reduce CMS star ratings for managed care organizations 
(MCOs). Proactive identification of patients at risk for future non-adherence can 
provide MCOs with a selective cost-effective approach to implement adherence 
intervention programs. The study aims to develop and validate a risk assessment 
tool (Prescription Medication Adherence Prediction Tool [RxAPT]) to predict non-
adherence to diabetes medications using Medicare claims data. METHODS: Claims 
data from 2012-2013 was used; data from previous year (baseline period) was used 
to predict adherence in the next year (follow-up period). Members 65 years and 
older with diabetes diagnosis, at least one prescription for diabetes medication, no 
insulin prescription, and continuously enrolled for both the years were included 
in the study. Adherence in the follow-up year was the study outcome, defined as 
proportion of days covered (PDC) ≥ 80%. A multiple logistic regression model was 
used to identify the final model using 70% of the data and risk scores were calcu-
lated using significant predictors from the model. The remaining 30% was used for 
cross-validation using split-sample method. Data from 2011-2012 was used to test 
the temporal validity of the tool. RESULTS: Total sample included 7028 patients. 
Seven significant predictors (all from pharmacy claims) were identified and used 
in the tool. Cross-validation statistics were as follows: C-statistics= 0.74, Hosmer-
Lemeshow goodness-of-fit p< 0.05, sensitivity= 0.71, specificity= 0.66, positive predic-
was intervention (yes/no). Other control variables included were demographics, 
physician specialty, health plan, CMS Risk Score, Charlson comorbidity index and 
number of other medications. RESULTS: In total, 186 hypertensive diabetic patients, 
non-adherent to ACE-Is/ARBs (PDC< 0.8) were identified. Among these patients, 29 
patients switched to other drug classes for treating diabetes and hypertension. After 
excluding those who switched, 157 patients were included in the logistic regression 
model with 131 continuing to use ACEI/ARBs and 26 discontinuing the ACEI/ARBs. 
Intervention and comorbidity index were found to be significantly associated with 
medication discontinuation. Patients who received intervention were more likely 
to persist with ACEI/ARBs (OR: 3.56, 95% CI: 1.06-11.86). Patients with higher CCI 
were more likely to discontinue and less likely to persist with ACEI/ARBs (OR: 0.72, 
95% CI: 0.53-0.99). Other covariates were not significantly associated with medica-
tion discontinuation. CONCLUSIONS: The brief pharmacist call was effective in 
preventing medication discontinuation. Future longer term studies are warranted 
to evaluate the effect of such interventions with other adherence outcomes such as 
proportion of days covered (PDC) and clinical outcomes like blood pressure control.
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OBJECTIVES: To determine patterns of learning diabetes care and how this impacts 
medication adherence among respondents with diabetes prescribed oral antidia-
betic (OAD) medications. METHODS: The Medical Expenditure Panel Survey (MEPS) 
household component full year consolidated data files (2010-2012) identified diabetes 
respondents (≥ 18 years) who received OAD medications and participated in the MEPS 
Diabetes Care Survey (DCS). Two groups were created from all eligible respondents 
based on how they learned diabetes care: 1) from a single primary care provider or 
medical specialist resource versus 2) multiple resources (medical provider plus inter-
net and/or group classes). OAD medication adherence was measured using the medi-
cation possession ratio (MPR). Respondents with MPR ≥ 0.8 were defined as adherent. 
Logistic regression identified significant socioeconomic factors associated with the 
learning approach (single provider versus multiple resources) used to learn diabetes 
care. RESULTS: A total of 1,347 respondents (58.5%, representing 12.6 million indi-
viduals in the U.S.) and 772 respondents (41.5%, representing 8.9 million individuals 
in the U.S.) learned about diabetes care from single resource and multiple resources 
respectively. Respondents reporting ages younger than 65 years, college degrees, high 
income levels, and treated with diet modification were more likely to learn diabetes 
care from multiple resources. No significant difference in MPR was observed between 
respondents learning diabetes care from a single provider resource (MPR= 0.66) versus 
multiple resources (MPR= 0.64, p= 0.245). Less than 45% of the respondents in both 
groups (single provider resource: 42.6%, multiple resources: 40.2%, p= 0.352) were 
adherent to OAD medications. CONCLUSIONS: Age, income and education levels, 
and whether being treated with diet modification influenced the approach to learning 
about diabetes care. Using medical providers only or multiple resources to learn about 
diabetes care had no impact on the OAD medication adherence.
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OBJECTIVES: To examine the effect of a brief pharmacist telephone intervention on 
adherence to ACE-Is/ARBs among non-adherent hypertensive patients with diabetes 
enrolled in a Texas-based Medicare Advantage plan. METHODS: The health plan 
medical claims data was used to identify patients with hypertension and diabetes 
diagnoses and at least 2 fills for ACE-Is or ARBs between January/2013-October/2013. 
Patients who failed to refill their medication for more than one day, and had a pro-
portion of days covered (PDC) < 0.8 were considered non-adherent and contacted 
by a pharmacist by phone. Descriptive statistics were conducted to assess the fre-
quency distribution of sample demographic characteristics at baseline. A multiple 
linear regression was conducted to assess the intervention effect on adherence 
during the 6 months post-intervention. The outcome variable was 6-month post 
intervention PDC. Other control variables included were baseline PDC, demograph-
ics, physician specialty (primary care vs. specialist), health plan (low income subsidy 
vs. not), CMS Risk Score, Charlson comorbidity index and number of other medica-
tions. RESULTS: A total of 131 patients were included in the analysis with 66 in the 
intervention group. The mean post intervention PDC for the intervention group was 
0.58 (SD±0.26) and 0.29 (SD±0.17) for the control group. Intervention was a significant 
predictor of better adherence in the linear regression model after adjusting for all 
the other baseline covariates (β = 0.318, p< 0.001), but the post intervention PDC was 
still lower than the generally accepted PDC of 0.8. Other covariates were not sta-
tistically significant. CONCLUSIONS: The brief pharmacist telephone intervention 
resulted in significantly better PDCs during the 6 months following the intervention 
but the overall PDC rates in both the intervention and control groups remained low. 
Future research should investigate the impact of behavior modifications which 
incorporate motivational interviewing and determine if this leads to a sustainable 
behavioral change and improved adherence.
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